535 related articles for article (PubMed ID: 16805946)
41. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic.
Rendić S
Croat Med J; 1999 Sep; 40(3):357-67. PubMed ID: 10411963
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenomics of antipsychotics efficacy for schizophrenia.
Cacabelos R; Hashimoto R; Takeda M
Psychiatry Clin Neurosci; 2011 Feb; 65(1):3-19. PubMed ID: 21265934
[TBL] [Abstract][Full Text] [Related]
43. The role of cytochrome P450 in antiretroviral drug interactions.
Walubo A
Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):583-98. PubMed ID: 17696808
[TBL] [Abstract][Full Text] [Related]
44. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?
Tomlinson B; Hu M; Lee VW
Mol Nutr Food Res; 2008 Jul; 52(7):799-809. PubMed ID: 18618477
[TBL] [Abstract][Full Text] [Related]
45. Cytochrome P450-mediated drug interactions.
Flockhart DA; Oesterheld JR
Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):43-76. PubMed ID: 10674190
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
Steimer W
Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
[TBL] [Abstract][Full Text] [Related]
48. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
Foti RS; Wahlstrom JL
IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
[TBL] [Abstract][Full Text] [Related]
49. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
[TBL] [Abstract][Full Text] [Related]
50. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
Urichuk L; Prior TI; Dursun S; Baker G
Curr Drug Metab; 2008 Jun; 9(5):410-8. PubMed ID: 18537577
[TBL] [Abstract][Full Text] [Related]
51. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination.
Bernauer U; Heinrich-Hirsch B; Tönnies M; Peter-Matthias W; Gundert-Remy U
Toxicol Lett; 2006 Jul; 164(3):278-88. PubMed ID: 16483733
[TBL] [Abstract][Full Text] [Related]
52. The potential pharmacological and toxicological impact of P450 screening.
Riley RJ
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):45-54. PubMed ID: 11727322
[TBL] [Abstract][Full Text] [Related]
53. A basic conceptual and practical overview of interactions with highly prescribed drugs.
Dresser GK; Bailey DG
Can J Clin Pharmacol; 2002; 9(4):191-8. PubMed ID: 12584577
[TBL] [Abstract][Full Text] [Related]
54. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
Muruganandan S; Sinal CJ
Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
[TBL] [Abstract][Full Text] [Related]
55. Cytochrome P450: another player in the myocardial infarction game?
Sunder-Plassmann R
Adv Clin Chem; 2007; 43():229-80. PubMed ID: 17249386
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenomics and therapeutic strategies for dementia.
Cacabelos R
Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
[TBL] [Abstract][Full Text] [Related]
58. The impact of pharmacogenetics on the development and use of antipsychotic drugs.
Reynolds GP
Drug Discov Today; 2007 Nov; 12(21-22):953-9. PubMed ID: 17993414
[TBL] [Abstract][Full Text] [Related]
59. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
Reynolds GP; Templeman LA; Zhang ZJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
[TBL] [Abstract][Full Text] [Related]
60. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
Bernard S; Neville KA; Nguyen AT; Flockhart DA
Oncologist; 2006 Feb; 11(2):126-35. PubMed ID: 16476833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
